Igea Pharma announced revenue expectations over the next three years of CHF 264 million globally, with an expected EBITDA margin in excess of 50 percent and expected net results of CHF 126 million of the joint venture the group will operate in the cannabis oil (CBD) market following the combination with Blue Sky...
